Bostwick
DG Pathology of benign prostatic hyperplasia. Kirby
RMcConnell
JFitzpatrick
JRoehrborn
CBoyle
Peds.Textbook of Benign Prostatic Hyperplasia. Oxford, England ISIS Medical Media Ltd1996;91- 104
Garraway
WMColins
GNLee
RJ High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991;338469- 471
Graves
EJGillum
BS Detailed diagnoses and procedures, National Hospital Discharge Survey, 1994. Vital Health Stat 13. 1997;1271- 145
Caine
M The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 1986;1361- 4
Lepor
HWilliford
WOBarry
MJ
et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996;335533- 539
Walsh
PC Treatment of benign prostatic hyperplasia. N Engl J Med. 1996;335586- 587
Braunwald
E Harrison's Principles of Internal Medicine. 11th ed. New York, NY McGraw Hill Book Co1987;364
Giovannucci
ERimm
EBChute
CG
et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140989- 1002
Gann
PHHennekens
CHLongcope
CVerhoek-Oftedahl
WGrodstein
FStampfer
MJ A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate. 1995;2640- 49
Rimm
EBStampfer
MJColditz
GAChute
CGLitin
LBWillett
WC Validity of self-reported waist and hip circumferences in men and women. Epidemiology. 1990;1466- 473
Barry
MJFowler
FJO'Leary
MP
et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;1481549- 1557
Welch
GKawachi
IBarry
MJGiovannucci
EColditz
GAWillett
WC Distinction between symptoms of voiding and filling in benign prostate hyperplasia: findings from the Health Professionals Follow-up Study. Urology. 1998;51422- 427
Chasen-Taber
SRimm
EBStampfer
MJ
et al. Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology. 1996;71- 6
Ainsworth
BEHaskell
WLLeon
AS
et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc. 1993;2571- 80
Girman
CJJacobsen
SJGuess
HA
et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol. 1995;1531510- 1515
Simpson
RJFisher
WLee
AJRussell
EBGarraway
M Benign prostatic hyperplasia in an unselected community-based population: a survey of urinary symptoms, bothersomeness and prostatic enlargement. Br J Urol. 1996;77186- 191
Craigen
AAHickling
JBSaunders
CRCarpenter
RG Natural history of prostatic obstruction: a prospective survey. J R Coll Gen Pract. 1969;18226- 232
Clarke
R The prostate and the endocrines: a control series. Br J Urol. 1937;9254- 271
Forray
CBard
JAWetzel
JM
et al. The α1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human α1c subtype. Mol Pharmacol. 1994;45703- 708
Marshall
IBurt
RPChapple
CR Noradrenaline contractions of human prostate mediated by α1A-(α1c-) adrenoceptor subtype. Br J Pharmacol. 1995;115781- 786
Hedlund
HAndersson
KELarsson
B Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. J Urol. 1985;1341291- 1298
Chapple
CRAubrey
MLJames
S
et al. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol. 1989;63487- 496
Shapiro
EBecich
MJHartanto
VLepor
H The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostatic hyperplasia. J Urol. 1992;1471293- 1297
Ishigooka
MHashimoto
THayami
SSuzuki
YSasagawa
INakada
T Correlation between morphometric differences and norepinephrine content in benign prostatic hyperplasia. Prostate. 1996;28385- 391
Kitada
SKumazawa
J Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue. J Urol. 1987;138158- 160
Shapiro
EHartanto
VLepor
H The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate. 1992;21297- 307
Kyprianou
NDavies
P Association states of androgen receptors in nuclei of human benign hypertrophic prostate. Prostate. 1986;8363- 380
Frydenberg
MFoo
TMJones
AS
et al. Benign prostatic hyperplasia: video image analysis and its relationship to androgen and epidermal growth factor receptor expression. J Urol. 1991;146872- 876
Peters
CAWalsh
PC The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987;317599- 604
Wilson
JD The pathogenesis of benign prostatic hyperplasia. Am J Med. 1980;68745- 756
Imperato-McGinley
JGuerrero
LGautier
TPeterson
RE Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;1861213- 1215
Andersson
SBerman
DMJenkins
EPRussell
DW Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature. 1991;354159- 161
Hackney
AC The male reproductive system and endurance exercise. Med Sci Sports Exerc. 1996;28180- 189
Wheeler
GDWall
SRBelcastro
ANCumming
DC Reduced serum testosterone and prolactin levels in male distance runners. JAMA. 1984;252514- 516